Etranacogene Dezaparvovec: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 4, p. 347, doi. 10.1007/s40265-023-01845-0
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2023 AND VI 83 AND IP 4
Results: 7
1
2
Olutasidenib: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 4, p. 341, doi. 10.1007/s40265-023-01844-1
- By:
- Publication type:
- Article
3
Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression.
- Published in:
- Drugs, 2023, v. 83, n. 4, p. 287, doi. 10.1007/s40265-023-01836-1
- By:
- Publication type:
- Article
4
Lecanemab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 4, p. 359, doi. 10.1007/s40265-023-01851-2
- By:
- Publication type:
- Article
5
Nadofaragene Firadenovec: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 4, p. 353, doi. 10.1007/s40265-023-01846-z
- By:
- Publication type:
- Article
6
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
- Published in:
- Drugs, 2023, v. 83, n. 4, p. 299, doi. 10.1007/s40265-023-01840-5
- By:
- Publication type:
- Article
7
Evolving Trends in Consumption of Direct Oral Anticoagulants in 65 Countries/Regions from 2008 to 2019.
- Published in:
- Drugs, 2023, v. 83, n. 4, p. 315, doi. 10.1007/s40265-023-01837-0
- By:
- Publication type:
- Article